The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
Frequently asked questions
What is the AdvisorShares Psychedelics ETF (PSIL) expense ratio?
The AdvisorShares Psychedelics ETF funds expense ratio is 0.99%.
What is AdvisorShares Psychedelics ETF (PSIL) current stock price?
As of the latest data, AdvisorShares Psychedelics ETF stock price is $20.67, with a previous close of $20.64. AdvisorShares Psychedelics ETF gained $0.03 in the last trading session, representing a 0.15% increase.
Does AdvisorShares Psychedelics ETF (PSIL) pay dividends?
No. AdvisorShares Psychedelics ETF does not pay a dividend.
